Martin Grass was born in 1964 and grew up in Harrisburg, Pennsylvania. After graduating from the University of Pennsylvania and doing an MBA at Cornell, he started working for Rite Aid, the pharmacy chain set up by his father, Alex, in 1962. In 1989 he was arrested for attempting to bribe a member of the Ohio state pharmacy board to step down in exchange for $33,000, although he was ultimately acquitted 15 months later when a judge ruled that the prosecution’s evidence was “circumstantial”. Despite this scandal, he took over from his father as both CEO and chairman of Rite Aid in 1995.
What was the scam?
When Martin Grass took over, Rite Aid was one of the largest pharmacy chains in America. Grass wanted to expand further, borrowing heavily to fund a string of acquisitions. In order to keep the share price soaring, despite mounting problems making repayments on this debt, Grass started to fiddle the books, using fake contracts (including with his brother-in-law’s firm) to make revenue and profits appear higher than they were. He also booked income prematurely, extended the period over which assets were depreciated and incorrectly recorded payments for medicine ordered but never collected.
What happened next?
The gap between the stated financials and reality grew so big that by October 1999 Rite Aid was forced to restate its earnings between 1997 and 1999, and lower its guidance for future profits, causing its shares to plunge by more than three-quarters. Grass was forced to resign, though it was later revealed that, even after he quit, he colluded to forge backdated documents giving several Rite Aid executives generous severance payments. He was charged with fraud in 2002 and sentenced in 2004 to eight years in jail.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Lessons for investors
Investigations revealed that Grass’s deceptions inflated profits by $1.6bn between 1997 and 1999. Rite Aid’s shares were trading at more than $50 at the start of 1999, but they fell to less than $10 a share by the end of the year, wiping more than $40bn off their value. At one point in 2009 they were trading at just $0.25. Borrowing large sums of money to fund expansion can work, but it can also create pressures on CEOs to cut corners. More generally, studies suggest that shares of firms with higher levels of debt tend to underperform.
-
Trump’s tariffs: what is he thinking and how should UK respond?Every right-thinking person knows that free trade is a surer route to the wealth of nations than protectionism, says Stuart Watkins. What is Trump thinking?
-
Barclays begins paying up to £100 compensation to customers after banking outageBarclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
Building firm Keller presents low debt and ample scope for growthGeotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
-
Pensions revolution: how to profit from the trends shaping the UK pension systemThe UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
